INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation Meeting Abstract
| Authors: | Mellinghoff, I. K.; Van Den Bent, M. J.; Blumenthal, D. T.; Touat, M.; Peters, K. B.; Clarke, J. L.; Mendez, J. S.; Welsh, L.; Mason, W. P.; Hottinger, A. F.; Sanchez, J. M. S.; Wick, W.; Soffietti, R.; Schoenfeld, S.; Dan, Z.; Pandya, S. S.; Steelman, L.; Hassan, I.; Wen, P. Y.; Cloughesy, T. F. |
| Abstract Title: | INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 17 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-10 |
| Language: | English |
| ACCESSION: | WOS:001043181100002 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2023.41.17_suppl.LBA1 |
| Notes: | Meeting Abstract: LBA1 -- Meeting was also available virtually -- Source: Wos |
